FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912982848> ?p ?o ?g. }

• W2912982848 endingPage "418" @default.
• W2912982848 startingPage "408" @default.
• W2912982848 abstract "Summary Background Prospectively designed studies assessing the exposure‐response profile of vedolizumab are lacking. Observational exposure‐response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly those that may affect vedolizumab clearance. Aims To (a) investigate the vedolizumab exposure‐response relationship after adjusting for potential confounding variables; (b) propose potential target serum vedolizumab concentrations for future study; (c) ascertain whether early vedolizumab serum concentrations were associated with short‐ and long‐term clinical outcomes in adults with ulcerative colitis in GEMINI 1. Methods Propensity‐score‐based case‐matching analysis was performed using data from GEMINI 1 and an earlier large population pharmacokinetic study, with vedolizumab clearance or concentration as predictors of clinical remission and response, adjusted for age, weight, anti‐tumour necrosis factor alpha therapy history, serum albumin and faecal calprotectin concentrations. Potential vedolizumab concentration targets at weeks 6, 14 and steady state were proposed. Association between early vedolizumab concentrations at weeks 2, 4 and 6 and clinical remission at weeks 14 and 52 was evaluated. Results Among 693 patients with pharmacokinetic data at week 6, potential target vedolizumab concentrations at weeks 6, 14 and steady state were 37.1, 18.4 and 12.7 µg/mL respectively. Week 6 was identified as the earliest time at which vedolizumab concentrations were consistently associated with clinical remission at weeks 14 and 52. Conclusions In this comprehensively adjusted analysis, vedolizumab concentrations at week 6 were associated with short‐ and long‐term remission. Potential induction and maintenance target concentrations were proposed for further study." @default.
• W2912982848 created "2019-02-21" @default.
• W2912982848 creator A5003590233 @default.
• W2912982848 creator A5005225915 @default.
• W2912982848 creator A5014598718 @default.
• W2912982848 creator A5019899259 @default.
• W2912982848 creator A5041912518 @default.
• W2912982848 creator A5060843899 @default.
• W2912982848 creator A5090566767 @default.
• W2912982848 date "2019-01-20" @default.
• W2912982848 modified "2023-09-30" @default.
• W2912982848 title "Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation" @default.
• W2912982848 cites W1940516511 @default.
• W2912982848 cites W1965832974 @default.
• W2912982848 cites W2003835888 @default.
• W2912982848 cites W2011837830 @default.
• W2912982848 cites W2017657896 @default.
• W2912982848 cites W2032346246 @default.
• W2912982848 cites W2040157712 @default.
• W2912982848 cites W2072240642 @default.
• W2912982848 cites W2077531651 @default.
• W2912982848 cites W2081071002 @default.
• W2912982848 cites W2092863985 @default.
• W2912982848 cites W2102245241 @default.
• W2912982848 cites W2118088660 @default.
• W2912982848 cites W2162805528 @default.
• W2912982848 cites W2191197545 @default.
• W2912982848 cites W2195373199 @default.
• W2912982848 cites W2414026316 @default.
• W2912982848 cites W2460337359 @default.
• W2912982848 cites W2469932435 @default.
• W2912982848 cites W2523706394 @default.
• W2912982848 cites W2556146932 @default.
• W2912982848 cites W2769684727 @default.
• W2912982848 cites W2773289068 @default.
• W2912982848 cites W2791118194 @default.
• W2912982848 cites W2792406291 @default.
• W2912982848 cites W2799380236 @default.
• W2912982848 cites W4210662453 @default.
• W2912982848 cites W4251926060 @default.
• W2912982848 cites W4296224660 @default.
• W2912982848 doi "https://doi.org/10.1111/apt.15113" @default.
• W2912982848 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6590294" @default.
• W2912982848 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30663076" @default.
• W2912982848 hasPublicationYear "2019" @default.
• W2912982848 type Work @default.
• W2912982848 sameAs 2912982848 @default.
• W2912982848 citedByCount "53" @default.
• W2912982848 countsByYear W29129828482019 @default.
• W2912982848 countsByYear W29129828482020 @default.
• W2912982848 countsByYear W29129828482021 @default.
• W2912982848 countsByYear W29129828482022 @default.
• W2912982848 countsByYear W29129828482023 @default.
• W2912982848 crossrefType "journal-article" @default.
• W2912982848 hasAuthorship W2912982848A5003590233 @default.
• W2912982848 hasAuthorship W2912982848A5005225915 @default.
• W2912982848 hasAuthorship W2912982848A5014598718 @default.
• W2912982848 hasAuthorship W2912982848A5019899259 @default.
• W2912982848 hasAuthorship W2912982848A5041912518 @default.
• W2912982848 hasAuthorship W2912982848A5060843899 @default.
• W2912982848 hasAuthorship W2912982848A5090566767 @default.
• W2912982848 hasBestOaLocation W29129828481 @default.
• W2912982848 hasConcept C112705442 @default.
• W2912982848 hasConcept C126322002 @default.
• W2912982848 hasConcept C17923572 @default.
• W2912982848 hasConcept C2776207728 @default.
• W2912982848 hasConcept C2778260677 @default.
• W2912982848 hasConcept C2778292693 @default.
• W2912982848 hasConcept C2779008522 @default.
• W2912982848 hasConcept C2779134260 @default.
• W2912982848 hasConcept C2780272996 @default.
• W2912982848 hasConcept C2780479503 @default.
• W2912982848 hasConcept C2908647359 @default.
• W2912982848 hasConcept C71924100 @default.
• W2912982848 hasConcept C77350462 @default.
• W2912982848 hasConcept C90924648 @default.
• W2912982848 hasConcept C99454951 @default.
• W2912982848 hasConceptScore W2912982848C112705442 @default.
• W2912982848 hasConceptScore W2912982848C126322002 @default.
• W2912982848 hasConceptScore W2912982848C17923572 @default.
• W2912982848 hasConceptScore W2912982848C2776207728 @default.
• W2912982848 hasConceptScore W2912982848C2778260677 @default.
• W2912982848 hasConceptScore W2912982848C2778292693 @default.
• W2912982848 hasConceptScore W2912982848C2779008522 @default.
• W2912982848 hasConceptScore W2912982848C2779134260 @default.
• W2912982848 hasConceptScore W2912982848C2780272996 @default.
• W2912982848 hasConceptScore W2912982848C2780479503 @default.
• W2912982848 hasConceptScore W2912982848C2908647359 @default.
• W2912982848 hasConceptScore W2912982848C71924100 @default.
• W2912982848 hasConceptScore W2912982848C77350462 @default.
• W2912982848 hasConceptScore W2912982848C90924648 @default.
• W2912982848 hasConceptScore W2912982848C99454951 @default.
• W2912982848 hasIssue "4" @default.
• W2912982848 hasLocation W29129828481 @default.
• W2912982848 hasLocation W29129828482 @default.
• W2912982848 hasLocation W29129828483 @default.
• W2912982848 hasOpenAccess W2912982848 @default.
• W2912982848 hasPrimaryLocation W29129828481 @default.

• next